Drug Approval | September 27, 2021
U.S. FDA approves Repatha for paediatric patients aged 10 years and older
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
